Jump Financial LLC Acquires 57,594 Shares of Insulet Corporation $PODD

Key Points

• Jump Financial LLC increased its stake in Insulet Corporation by 3,824.3% during the first quarter, acquiring an additional 57,594 shares to hold a total of 59,100 shares valued at approximately $15.5 million.
• Insulet reported strong quarterly earnings, with $1.17 earnings per share, exceeding estimates by $0.25, and a 32.9% year-over-year revenue growth to $649.1 million.
• Analyst upgrades for Insulet include a target price increase from Canaccord Genuity from $331.00 to $353.00, with the overall sentiment being a "Moderate Buy" from 16 analysts.

Jump Financial LLC raised its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 3,824.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 59,100 shares of the medical instruments supplier's stock after purchasing an additional 57,594 shares during the period. Jump Financial LLC owned 0.08% of Insulet worth $15,520,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in PODD. Larson Financial Group LLC increased its stake in shares of Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 81 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in shares of Insulet during the first quarter valued at approximately $26,000. SouthState Corp increased its stake in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 76 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Insulet during the fourth quarter valued at approximately $42,000. Finally, Ramirez Asset Management Inc. bought a new position in shares of Insulet during the first quarter valued at approximately $53,000.

Insulet Trading Up 0.9%

Shares of PODD stock opened at $330.77 on Friday. Insulet Corporation has a 12-month low of $180.31 and a 12-month high of $334.18. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm's 50 day moving average is $300.94 and its 200 day moving average is $285.91. The stock has a market capitalization of $23.28 billion, a P/E ratio of 100.54, a P/E/G ratio of 2.77 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. During the same quarter last year, the company posted $0.55 earnings per share. The firm's quarterly revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of analyst reports. Canaccord Genuity Group raised their target price on shares of Insulet from $331.00 to $353.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Citigroup reissued a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Truist Financial initiated coverage on shares of Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 price target for the company. Wells Fargo & Company raised their price target on shares of Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Sixteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, Insulet presently has an average rating of "Moderate Buy" and a consensus target price of $332.71.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.